Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury
1 Department of Cardiology, Pozna
University of Medical Sciences, Cardiac and Rehabilitation Hospital, ul. Sanatoryjna 34, 64-600 Kowanówko k/Obornik Wlkp, Poland
2 Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, The Netherlands
* Corresponding author. Tel: +48 602217202; fax: +48 612977500. E-mail address: tomasz.siminiak{at}usoms.poznan.pl
Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.
Key Words: Heart failure Myoblasts Cell transplantation Catheter systems